PDCD1 and hepatocellular carcinoma: With these limitations in mind, we strongly recommend that further exploration should be undertaken to maximize sample size in different risk strata to identify more effective antiviral regimens, and to optimize prevention of HBVr and management of HCC patients with PD-1 inhibitors.